Extreme exhausting; Redness at site of shot (3 inches * 2 inches wide of redness).; Pain at site of shot; Itchiness at site of shot; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE ERYTHEMA (Redness at site of shot (3 inches * 2 inches wide of redness).), VACCINATION SITE PAIN (Pain at site of shot), VACCINATION SITE PRURITUS (Itchiness at site of shot) and FATIGUE (Extreme exhausting) in an 85-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     NO Medical History Information was reported.     On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness at site of shot (3 inches * 2 inches wide of redness).), VACCINATION SITE PAIN (Pain at site of shot) and VACCINATION SITE PRURITUS (Itchiness at site of shot). On an unknown date, the patient experienced FATIGUE (Extreme exhausting). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE ERYTHEMA (Redness at site of shot (3 inches * 2 inches wide of redness).), VACCINATION SITE PAIN (Pain at site of shot), VACCINATION SITE PRURITUS (Itchiness at site of shot) and FATIGUE (Extreme exhausting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 16-Feb-2021 and was forwarded to Moderna on 16-Feb-2021.    This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE ERYTHEMA (Redness at site of shot (3 inches * 2 inches wide of redness).), VACCINATION SITE PAIN (Pain at site of shot), VACCINATION SITE PRURITUS (Itchiness at site of shot) and FATIGUE (Extreme exhausting) in an 85-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     NO Medical History Information was reported.     On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness at site of shot (3 inches * 2 inches wide of redness).), VACCINATION SITE PAIN (Pain at site of shot) and VACCINATION SITE PRURITUS (Itchiness at site of shot). On an unknown date, the patient experienced FATIGUE (Extreme exhausting). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE ERYTHEMA (Redness at site of shot (3 inches * 2 inches wide of redness).), VACCINATION SITE PAIN (Pain at site of shot), VACCINATION SITE PRURITUS (Itchiness at site of shot) and FATIGUE (Extreme exhausting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.